Abstract 5599: NXP900, a novel YES1/SRC kinase inhibitor currently in clinical development, blocks YAP1 signaling in NSCLC cell lines
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-5599
Abstract: Most kinase inhibitors exert their anticancer effects by targeting the ATP binding site, either binding and locking an active or inactive kinase conformation, with targeting inactive conformation typically leading to a superior selectivity profile1. NXP900… read more here.
Keywords: cell lines; cell; nsclc cell; inhibitor ... See more keywords
Abstract 374: Etv2 Transcriptionally Regulates Yes1 and Promotes Cell Proliferation During Embryogenesis
Sign Up to like & getrecommendations! Published in 2019 at "Circulation Research"
DOI: 10.1161/res.125.suppl_1.374
Abstract: Etv2, an Ets-transcription factor, governs the specification of the earliest hemato-endothelial progenitors during embryogenesis. While the transcriptional networks during hemato-endothelial development have been well described, the mechanistic details are incompletely defined. In the present study,… read more here.
Keywords: embryogenesis; cell cycle; proliferation; yes1 ... See more keywords